Efficacy and safety of topical corticosteroid treatment under occlusion for severe alopecia areata in children: a single-centre retrospective analysis
Clinical and Experimental Dermatology · 2024
DOI: 10.1093/ced/llae085 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2024. Verfasst von Young Yoon Lee und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, School of Medicine, Chungnam National University, Daejeon, Republic of Korea. Hauptthemen laut MEDLINE: Alopecia Areata, Clobetasol. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben. Gefördert von: Basic Science Research, National Research Foundation of Korea, Ministry of Education, Science and Technology.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Alopecia areata (AA) has a poor clinical course in children. There are no reliable therapeutic options for children with severe AA, including alopecia totalis (AT) and alopecia universalis (AU).
Objectives
We evaluated the efficacy and adverse effects of a potent topical corticosteroid (TCS) under occlusion in paediatric patients with severe AA.
Methods
We reviewed records of 23 patients under the age of 10 years with AT or AU treated with a potent TCS (0.05% clobetasol propionate or 0.3% diflucortolone valerate) for 8 h under occlusion with a plastic film. We used the Severity of Alopecia Tool (SALT) to measure clinical improvement. The primary endpoint was a SALT score of ≤ 20 at 6 months. We analysed the change in cortisol levels to identify the long-term safety of TCS therapy on the hypothalamus–pituitary–adrenal axis.
Results
Nineteen of the 23 patients (83%) reached SALT ≤ 20 at 6 months. Six patients relapsed over the 6-month follow-up period. Four patients were suspected of having adrenal insufficiency. However, the cortisol levels of the patients recovered to normal within 1 month of lowering the TCS potency or changing to nonsteroidal treatments. Limitations include the retrospective design and small sample size.
Conclusions
This study shows that a potent TCS occlusion may be a safe treatment option in paediatric patients with severe AA. Further long-term studies are required to evaluate the safety and recurrence of TCS occlusion therapy for paediatric AA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, School of Medicine, Chungnam National University, Daejeon, Republic of Korea.
- Department of Pediatrics, School of Medicine, Chungnam National University, Daejeon, Republic of Korea.
ORCID-Profile: Young Yoon Lee
Förderung
- Basic Science Research
- National Research Foundation of Korea
- Ministry of Education, Science and Technology
Zitieren
APA
Lee, Y. Y., Lim, H. H., Son, S., Jin, S., Shin, J. M., Hong, D. K., Jung, K. E., Seo, Y. J., Lee, T. K., Kim, Y. M., & Lee, Y. (2024). Efficacy and safety of topical corticosteroid treatment under occlusion for severe alopecia areata in children: a single-centre retrospective analysis. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llae085
Vancouver
Lee YY, Lim HH, Son S, Jin S, Shin JM, Hong DK, et al. Efficacy and safety of topical corticosteroid treatment under occlusion for severe alopecia areata in children: a single-centre retrospective analysis. Clinical and Experimental Dermatology. 2024. doi:10.1093/ced/llae085
BibTeX
@article{Lee2024,
author = {Lee, Young Yoon and Lim, Han Hyuk and Son, Seungjin and Jin, Soyoung and Shin, Jung-Min and Hong, Dong-Kyun and Jung, Kyung Eun and Seo, Young-Joon and Lee, Tae Kwan and Kim, Yoo-Mi and Lee, Young},
title = {Efficacy and safety of topical corticosteroid treatment under occlusion for severe alopecia areata in children: a single-centre retrospective analysis},
journal = {Clinical and Experimental Dermatology},
year = {2024},
doi = {10.1093/ced/llae085}
}
EUVIMED